CERS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Cerus Corp (CERS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong long-term growth potential, supported by analyst confidence, a discounted valuation, and a positive technical setup. While financial performance shows some weaknesses, the company's revenue growth and strategic partnerships provide a solid foundation for future gains.
The technical indicators for CERS are bullish. The MACD is positive and expanding, the RSI is neutral at 73.434, and the moving averages are aligned in a bullish pattern (SMA_5 > SMA_20 > SMA_200). The stock is trading above key pivot levels, with resistance at 2.575 and 2.71, and support at 2.355 and 2.135.
Analyst confidence in the sustainability of double-digit revenue growth and the attractiveness of the current discounted valuation.
Strategic partnership with BCA to accelerate adoption and profitability.
Revenue growth of 18.91% YoY in Q3 2025.
Net income dropped significantly (-99.35% YoY) in Q3
EPS declined to 0, down 100% YoY.
Gross margin slightly decreased by 2.71% YoY.
In Q3 2025, Cerus Corp reported an 18.91% YoY increase in revenue to $60.24M. However, net income dropped to -$19,000 (-99.35% YoY), and EPS fell to 0 (-100% YoY). Gross margin decreased slightly to 59.23% (-2.71% YoY).
TD Cowen has a Buy rating on CERS with a price target of $5. The firm highlights the company's Intercept Fibrinogen Complex franchise and strategic partnerships as key drivers for long-term growth and profitability.
